Mucormycosis in COVID-19 patients

Natarajan, Sundaram; Bhende, Tejas; Yashwant, Runali; Jadhav, Siddhita; Jain, Astha

doi:10.4103/ijo.ijo_1316_21

Cited by 16 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The nasal turbinates are frequently the initial site of infection. However, the aggressive nature of this fungal pathogen enables it to rapidly spread, affecting the sinuses, palate, eyes, and alarmingly, the brain by invading blood vessels, causing ischemia and subsequent necrosis (8). The global rise of the COVID-19 pandemic, which has profoundly impacted healthcare, has led to a resurgence in mucormycosis cases, commonly known as 'black fungus.'…”

Section: Discussionmentioning

confidence: 99%

Mucormycosis Following COVID-19: A Comprehensive Case Series Investigation

Ghazizadeh,

Mohseni,

Asadi

et al. 2024

Arch Clin Infect Dis

View full text Add to dashboard Cite

Background: Mucormycosis, commonly referred to as 'black fungus,' has arisen as a complication associated with COVID-19. Objectives: This research investigated the clinical features, demographic profiles, and outcomes of patients with mucormycosis during the COVID-19 pandemic. Methods: A case series involving 29 patients diagnosed with mucormycosis was conducted. The study systematically examined demographic information, underlying health conditions, COVID-19 status, and clinical outcomes of these patients. Results: The majority of patients, accounting for 90%, developed mucormycosis subsequent to COVID-19 infection, with diabetes mellitus being the predominant comorbidity, affecting 38% of cases. A higher incidence was observed in males, and the mortality rate was significant. Functional endoscopic sinus surgery (FESS) was utilized for both diagnosis and treatment, although the success rate of this procedure varied. Conclusions: Post-COVID-19 mucormycosis presents intricate clinical challenges, particularly in patients with comorbidities and weakened immune systems. Prompt diagnosis and a comprehensive, multidisciplinary approach are crucial. Additional research is needed to enhance our comprehension and improve treatment strategies for this daunting infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Mucormycosis Following COVID-19: A Comprehensive Case Series Investigation

Ghazizadeh,

Mohseni,

Asadi

et al. 2024

Arch Clin Infect Dis

View full text Add to dashboard Cite

show abstract

“…There have also been reports of PM mimicking a lung tumor [ 8 , 9 ]. The infection tends to be fatal without timely diagnosis and treatment and its mortality rate is reported to be over 50% [ 10 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Oral Isavuconazole Combined with Nebulized Inhalation and Bronchoscopic Administration of Amphotericin B for the Treatment of Pulmonary Mucormycosis: A Case Report and Literature Review

Leng,

Zhou,

et al. 2024

JoF

View full text Add to dashboard Cite

Pulmonary mucormycosis (PM) is an invasive and potentially fatal fungal infection, with Rhizopus microsporus (R. microsporus) being the most common pathogen. The routine therapy for this infection includes surgery and antifungal agents. However, the therapeutic effects of single agents are unsatisfactory due to the rapid progression of mucormycosis, while not all patients can tolerate surgery. Innovative treatment methods like combination therapy await validations of their clinical efficacy. We report a case of PM that was diagnosed via metagenomics next-generation sequencing (mNGS) of black drainage fluid from the patient’s lung. The patient eventually recovered and was discharged after a combination therapy of oral isavuconazole, inhaled amphotericin B, and local perfusion of amphotericin B through bronchoscopy, which may be a promising strategy for the treatment of PM, especially for cases where surgery is not possible. A retrospective study of 297 cases in a literature review highlights the different treatment methods used in clinical practice.

show abstract

“…Mucor mycosis infections are characterized by extensive angioinvasion that results in vessel thrombosis and subsequent tissue necrosis [1] which leads to increased mortality. It thus becomes important not only for the medical fraternity but also for the general population [11] to build awareness about the same during second wave when Mucor mycosis cases in COVID-19 patients created an alarm in the country. Mucor mycosis has been declared an epidemic in several Indian states and has been classified as a notifiable disease [12].…”

Section: Introductionmentioning

confidence: 99%

Mucor Mycosis and Other Fungal Infections in Covid-19 Patients During Second Wave of Pandemic at a Tertiary Care Hospital

2023

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objectives: In India, there has been a sudden Surge in Mucor mycosis cases during second wave of COVID-19, made the Government of India declare it as a notifiable disease. In this background, we did a study to know the fungal etiology of the suspected Mucor mycosis cases and to know the positivity rate of Mucor mycosis in COVID-19 patients during the second wave of the COVID-19 pandemic. Methods: In a retrospective study, we examined different samples from 112 Covid-19 positive, in-patients with suspected Mucor mycosis. A history of risk factors was taken. Potassium hydroxide (KOH) mount was done for all samples followed by culture on Sabouraud’s dextrose agar. Results: 81.25% of total cases were from 31 to 60 years of age group. Diabetes mellitus, steroid therapy, and Intensive care unit admissions were the risk factors observed. Fungal filaments were observed in 37 samples in KOH mount (33%) and culture was positive in 45 samples (40.17%). Mixed infection was seen in two cases (4.44%). The most common fungus isolated was Mucor in 23 samples (48.93%) followed by Aspergillus in 7 cases (14.89%; Aspergillus niger in four cases, Aspergillus fumigatus in 2 cases and Aspergillus flavus in 1 case) and Candida spp in 6 cases (12.76%). Among mixed infections, Mucor and A. niger in one case and Candida and A. niger in another case were isolated. Rhyzopus, Syncephalastrum, Penicillium, and Fusarium were the other fungi isolated. Conclusion: Mucorales were the most common species isolated (63.82%) followed by Aspergillus species. High suspicion and diagnosis of Mucor mycosis in Covid-19 patients is very important to initiate antifungal treatment, to reduce the mortality.

show abstract

Mucormycosis in COVID-19 patients

Cited by 16 publications

References 28 publications

Mucormycosis Following COVID-19: A Comprehensive Case Series Investigation

Mucormycosis Following COVID-19: A Comprehensive Case Series Investigation

Oral Isavuconazole Combined with Nebulized Inhalation and Bronchoscopic Administration of Amphotericin B for the Treatment of Pulmonary Mucormycosis: A Case Report and Literature Review

Mucor Mycosis and Other Fungal Infections in Covid-19 Patients During Second Wave of Pandemic at a Tertiary Care Hospital

Contact Info

Product

Resources

About